- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: Dimer Acid.
Displaying page 1 of 2.
EudraCT Number: 2018-003139-31 | Sponsor Protocol Number: 38RC18.103 | Start Date*: 2018-12-04 |
Sponsor Name:CHU GRENOBLE ALPES | ||
Full Title: Efficacy and safety of levocetirizine alone or in combination with tranexamic acid in the treatment of spontaneous chronic urticaria. Multicentric controlled randomized study in cross-over, double-... | ||
Medical condition: Chronique Spontaneous urticaria | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002190-10 | Sponsor Protocol Number: UCDCRC/20/03 | Start Date*: 2021-02-05 |
Sponsor Name:University College Dublin | ||
Full Title: Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) | ||
Medical condition: Coagulopathy of COVID-19 appears to afflict approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by ele... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001092-49 | Sponsor Protocol Number: VPA-03 | Start Date*: 2015-06-02 | |||||||||||
Sponsor Name:Sahlgrenska Akademien Wallenberglaboratoriet | |||||||||||||
Full Title: Valproic acid regulation of plasma PAI-1 | |||||||||||||
Medical condition: The fibrinolytic system | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003959-11 | Sponsor Protocol Number: 1703001 | Start Date*: 2020-05-25 |
Sponsor Name:Vestre Viken Trust | ||
Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) follow-up study | ||
Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019643-19 | Sponsor Protocol Number: 3/19/2010 | Start Date*: 2011-01-13 |
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I, Abt.f.Hämatologie u.Hämostaseologie | ||
Full Title: The effect of clopidogrel and prasugrel with and without acetylsalicylic acid (ASA) on hemostatic system activation at the site of plug formation in vivo in man | ||
Medical condition: coronary artery disease and acute coronary syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004666-15 | Sponsor Protocol Number: TMC-MDC-11-01 | Start Date*: 2012-04-03 |
Sponsor Name:The Medicines Company | ||
Full Title: A Phase II, double-blind, parallel group, dose-selection study to compare antifibrinolytic MDCO-2010 vs. placebo and tranexamic acid in reducing blood loss in patients undergoing primary cardiac su... | ||
Medical condition: Primary cardiac surgery involving cardiopulmonary bypass | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-006130-12 | Sponsor Protocol Number: Asperum | Start Date*: 2021-03-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Multicenter randomized, double-blind, placebo-controlled, clinical trial of Acetylsalicylic acid in the prevention of severe COVID-19 pneumonia in hospitalised patients (Asperum) | |||||||||||||
Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002722-36 | Sponsor Protocol Number: RAGTIME | Start Date*: 2017-03-29 | |||||||||||
Sponsor Name:FUNDACIÓ LLUITA CONTRA LA SIDA | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of Raltegravir intensification (1.200 mg QD) on the gut microbiota of chronically HIV-1 infected subject over time... | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001428-38 | Sponsor Protocol Number: RRK2939 | Start Date*: 2006-09-18 |
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | ||
Full Title: Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy | ||
Medical condition: Patients with early inflamatory arthritis (duration of symptoms of < 12 weeks) who are at very high risk of the development of rheumatoid arthritis (seropositivity for Rheumatoid factor and anti-C... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001172-15 | Sponsor Protocol Number: APN01-01-COVID19 | Start Date*: 2020-04-08 |
Sponsor Name:APEIRON Biologics AG | ||
Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 | ||
Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2016-003246-93 | Sponsor Protocol Number: D3461C00008 | Start Date*: 2016-12-06 |
Sponsor Name:Astrazeneca AB | ||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... | ||
Medical condition: Systemic Lupus Erythematosus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001305-41 | Sponsor Protocol Number: MicroVasc-DIVA | Start Date*: 2014-11-25 |
Sponsor Name:GWT-TUD GmbH | ||
Full Title: MICROVASCULAR AND ANTIINFLAMMATORY EFFECTS OF RIVAROXABAN COMPARED TO LOW DOSE ASPIRIN IN TYPE 2 DIABETIC PATIENTS WITH VERY HIGH CARDIOVASCULAR RISK AND SUBCLINICAL INFLAMMATION | ||
Medical condition: Patients with type 2 diabetes and stable cardiovascular disease (CVD) and low grade inflammation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002312-43 | Sponsor Protocol Number: 01052020 | Start Date*: 2020-05-28 |
Sponsor Name:Miguel Cervero Jiménez, servicio de Medicina Interna, Hospital Universitario Severo Ochoa | ||
Full Title: Clinical trial, PHASE III, randomized, open-label, to evaluate the efficacy of administering high-dose cholecalciferol orally alongside standard therapy in patients with COVID-19 pneumonia (COVID-1... | ||
Medical condition: COVID-19 PNEUMONIA | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003575-21 | Sponsor Protocol Number: | Start Date*: 2017-07-25 | |||||||||||
Sponsor Name:MRC Clinical Trials Unit at UCL | |||||||||||||
Full Title: A multicentre, 48 week randomised controlled factorial trial of adding maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy. | |||||||||||||
Medical condition: Hepatic steatosis in adults with chronic HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000641-33 | Sponsor Protocol Number: PAX | Start Date*: 2022-04-21 | |||||||||||
Sponsor Name:Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència | |||||||||||||
Full Title: Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study | |||||||||||||
Medical condition: Post-Acute-Covid-19 Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002299-11 | Sponsor Protocol Number: SD-COVID19-01 | Start Date*: 2020-09-17 | |||||||||||
Sponsor Name:SigmaDrugs Research Ltd. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety and efficacy of daily 200 mg fluvoxamine as add-on therapy to standard of care in moderate severity COVID-... | |||||||||||||
Medical condition: SARS-CoV-2 infected patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000497-30 | Sponsor Protocol Number: FIS-VED-2017-01 | Start Date*: 2018-05-28 | |||||||||||
Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI) | |||||||||||||
Full Title: Phase II clinical trial to evaluate the safety and efficacy of Vedolizumab combined with antiretroviral treatment to achieve functional healing in people infected with HIV-1 without previous antire... | |||||||||||||
Medical condition: Adult patients infected with HIV and without previous antiretroviral treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000610-10 | Sponsor Protocol Number: RivAsA | Start Date*: 2020-01-27 | ||||||||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | ||||||||||||||||||
Full Title: Effects of low-dose Rivaroxaban combined with low-dose Aspirin versus low-dose aspirin alone on in vivo platelet Activation, endothelial function and inflammation in type 2 diabetic patients with s... | ||||||||||||||||||
Medical condition: type 2 diabetic patients with stable peripheral or carotid artery disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001693-33 | Sponsor Protocol Number: ITL-2002-CL-001 | Start Date*: 2022-03-30 | |||||||||||
Sponsor Name:Intellia Therapeutics, Inc. | |||||||||||||
Full Title: Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE) | |||||||||||||
Medical condition: Hereditary Angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001406-42 | Sponsor Protocol Number: 30032016 | Start Date*: 2016-12-20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.